22nd Nov 2013 14:10
LONDON (Alliance News) - AstraZeneca PLC and its partner Bristol-Myers Squibb Friday announced that the Committee for Medicinal Products For Human Use has recommending approval of type 2 diabetes treatment.
The major pharmaceutical company said the committee from the European Medicines Agency adopted a positive opinion of its drug Xiqduo for the use of adults aged 18 or over.
The drug has been recommended as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their current type 2 diabetes treatment regimen or who are currently being treated with the combination of dapgliflozin and metformin as separate tablets.
The positive recommendation for Xigduo will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland and Norway.
AstraZeneca shares were up 1.6% to 3,453.50 pence, putting it in the top ten FTSE 100 movers Friday.
By Tom McIvor; [email protected]; @TomMcIvor1
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca